Interius BioTherapeutics is set to participate in several upcoming scientific meetings focused on gene and cell therapies.

The company will present at Cellicon Valley '25 from April 30 to May 2, where CEO Philip Johnson will lead a session titled 'Are In Vivo Cell Therapies the Key to the Future of Medicine?'

Bishop's presentation is scheduled for May 9 at 9:15 am CT, where he will address overcoming manufacturing bottlenecks in in vivo cell engineering.

Interius BioTherapeutics specializes in engineering targeted vectors for genetic medicine delivery, aiming to enhance existing CAR T-cell therapies by creating CAR cells directly within the patient.

Johnson will also deliver a presentation on 'Cell-specific in vivo gene delivery: A pipeline dream no longer' on May 1 at 3:50 pm EDT.

At the ISCT 2025 Annual Meeting in New Orleans from May 7 to 10, Dr. David Bishop will present findings from the Phase 1 clinical trial of INT2104, which focuses on CAR T and CAR NK cell generation for B cell malignancies.

Interius will also present at the ASGCT 28th Annual Meeting from May 13 to 17, with Johnson discussing investigational in vivo CAR-T therapy on May 15 from 3:45 to 5:30 pm CT.

The company's innovative approach seeks to eliminate reliance on preconditioning chemotherapy and reduce manufacturing costs for CAR T-cell treatments.